Revolution Medicines reported positive Phase III results for daraxonrasib (RMC-6236), an orally administered RAS-targeting therapy in metastatic pancreatic ductal adenocarcinoma. In the RASolute 302 trial, daraxonrasib extended survival metrics versus standard cytotoxic chemotherapy, with a reported median overall survival of 13.2 months compared with 6.7 months. The company framed the benefit across a range of RAS variants, while noting generally manageable safety and “no new safety signals.” The outcome adds pressure to the broader pancreatic oncology pipeline as RAS-directed approaches move closer to potential regulatory review and label expansion.